Illinois: Project PrEPare, AIDS Foundation of Chicago Hold HIV Drug Forum
December 23, 2010
The AIDS Foundation of Chicago (AFC) and Project PrEPare recently hosted a community forum to discuss next steps after a study showed an HIV drug could prevent infection in healthy gay men.
AFC Director of Advocacy Jim Pickett and Keith Green, director for Project PrEPare, a Chicago-based component of the international iPrEx study, moderated the discussion of potential risks and benefits of pre-exposure prophylaxis (PrEP). The study of men who have sex with men (MSM) and transgender persons who have sex with men found those who received daily emtricitabine plus tenofovir (Truvada) -- and also condoms, counseling, and other prevention services -- saw their infection risk cut by 43.8 percent. Participants with even better drug adherence realized more protection, up to 72.8 percent.
Dr. Sybil Hosek, a principal investigator for Project PrEPare, noted iPrEx is the first study of its kind. "The folks at iPrEx recognize that there is still a lot that needs to be understood," she said.
iPrEx recently began an open-label extension of the study, which allows participants who were on a placebo during the trial to take Truvada, said Hosek.
Project PrEPare's study is less focused on the efficacy of Truvada and more about the acceptability and feasibility of a PrEP trial among a potentially high risk, young MSM demographic, Hosek said.
Panelists, who included Dr. Lisa Henry-Reid and Dr. Margo Bell of Project PrEPare, addressed attendees' questions about various aspects of the prophylactic use of the medication.
Windy City Times (Chicago)
12.22.2010; Tully Satre
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
Add Your Comment:
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)